Blog

Via: https://www.biospace.com/article/biotech-companies-are-expanding-the-frontiers-of-engineered-cell-therapy-/ Published: Nov 11, 2021 By Maggie Chen The plasticity of a cell is one of its quietly profound advantages – picture cells glowing from an extraneous DNA vector incorporated into the genome or cells that acquire newfound targeting abilities to find and kill problematic

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. If granted, AZD7442 would be the first LAAB to receive an EUA

Via: https://www.biospace.com/article/exciting-clinical-news-out-of-the-european-society-for-medical-oncology-congress-2021 |Published: Sep 17, 2021 By Mark Terry Biopharma companies big and small are presenting exciting clinical studies at the European Society for Medical Oncology Congress 2021. Here’s a look at just some of those highlights: Amgen announced the first combination study results from the Phase Ib/II

Via: https://www.biospace.com/article/covid-19-us-expected-to-recommend-boosters-and-more/ Published: Aug 17, 2021 By Mark Terry What’s Next for COVID-19? All Signs Point to Boosters As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of

via: https://www.biospace.com/article/noting-delta-variant-pfizer-biontech-plan-to-ask-fda-for-eua-for-booster-shot/ Published: Jul 09, 2021 By Mark Terry Pfizer and BioNTech report a plan to request Emergency Use Authorization (EUA) for third booster shots for their COVID-19 vaccine. The two companies cited initial data from a clinical trial that showed a booster dose given six months

via: https://www.biospace.com/article/new-ceos-named-at-two-top-pharma-companies Published: Jul 08, 2021 By Vanessa Doctor, RN Two chief executive officers (CEOs) were named to biotech and pharmaceutical companies today. Boston-based oncology company Scorpion Therapeutics has announced the appointment of a new chief executive offer to help drive the firm’s cancer care programs. Dr. Axel Hoos joins the company

Novartis today announced the launch of More Than Just Words, a multiyear commitment to promote health equity in breast cancer care, where there is significant unmet need. Black women under the age of 35 are diagnosed with breast cancer at twice the rate of white

COVID-19-Related Biophytiscompleted recruitment of 155 patients to its COVA Phase II/III trial of Sarconeos in COVID-19 patients. This will allow the independent Data Monitoring Committee to run its second interim analysis. Sarconeos is an oral, small molecule being developed for sarcopenia in a Phase II trial,

via: https://www.inc.com/anis-uzzaman/top-business-technology-trends-in-2021.html By: Anis Uzzaman, General Partner and CEO, Pegasus Tech Ventures 2020’s Covid-19 pandemic has helped us all become acquainted with uncertainty. Companies are in a hurry to develop new digital capabilities in an effort to build resilience and retool for the post-pandemic world. Here

2020 is almost over but before we wave goodbye, R&D Partners wanted to give back to charities near and dear to us. We asked our employees to pick a foundation and make a donation. Here’s a list of all the amazing places we were able

Via: https://www.biospace.com/article/u-s-government-banks-on-vaccines-from-multiple-companies-to-end-pandemic/ Published: Dec 09, 2020 By Alex Keown The U.S. Food and Drug Administration (FDA) is on the cusp of approving the first vaccines against the novel coronavirus, delivering a potential end to the pandemic. Although vaccines will be available pending approval, there are questions

The Nobel Prize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna for the development of a method for genome editing. They discovered one of gene technology’s sharpest tools: the CRISPR/Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants

Via: https://www.biospace.com/article/astrazeneca-expands-phase-iii-covid-19-vaccine-trial-into-the-u-s-/ AstraZeneca announced that its Phase III clinical trial of its COVID-19 vaccine  candidate, AZD1222, is expanding into the U.S. It will be dubbed D8110C00001 and is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). The

VIA: https://scitechdaily.com/rare-boomerang-earthquake-tracked-by-scientists-in-the-ocean-for-the-first-time By IMPERIAL COLLEGE LONDON Scientists observed a ‘boomerang’ earthquake along Atlantic Ocean fault line, providing clues about how they could cause devastation on land. Earthquakes occur when rocks suddenly break on a fault – a boundary between two blocks or plates. During large earthquakes,

Are you in a leadership position in your company right now? Or do you aspire to be in that position someday? No matter where you are, these qualities can be worked on right now. If you want to be a good leader, they’re essential to

Sanofi Pasteur, the vaccines business unit of Paris-based Sanofi, and Lexington, Massachusetts-based Translate Bioannounced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases. The original deal was entered in 2018. Under the new deal expansion, Sanofi will pay Translate Bio $425 million up

The rapid advancement of technology throughout the last few decades has led to huge leaps forward in our ability to collaborate, produce, and multitask in the workplace. However, with the influx of new technologies, we are now capable of multitasking even to our own detriment.